I'm bullish on Harrow due to the VEVYE Access for All program, which makes dry eye treatment affordable and drives strong prescription growth. VEVYE's discounted pricing addresses a massive, ...
Harrow's focused acquisition model in ophthalmic drugs enables high growth, with a diversified portfolio and limited R&D expenses. My DCF analysis suggests a fair value of $72.75 per share—nearly 100% ...
Hosted on MSN
Harrow, Inc. (HROW) Emerges as Eye Care Powerhouse With Biosimilars to Lucentis and Eylea
We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Harrow, Inc. is one of them. Harrow, Inc. (NASDAQ:HROW), a leading U.S.-based pharmaceutical company, is ...
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Energy Transfer LP (NYSE:ET). “The pipes are a great business here, they really are,” he added. On the earnings front, Energy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback